Vara
Better breast cancer screening should be a universal offering to every woman in the world. Vara’s AI-powered software platform, created with screening radiologists in Germany, mitigates much of the human subjectivity associated with reading mammography results—and reduces the repetitive work screening physicians are routinely subjected to—we’re making breast cancer screening more effective, more measurable, and more accessible for everyone, everywhere. By democratising access to early screening around the world, we deliver measurable impact backed by clinical evidence. We are partnering globally, to deliver breast cancer screening where it is needed most.
Vara
Better breast cancer screening should be a universal offering to every woman in the world. Vara’s AI-powered software platform, created with screening radiologists in Germany, mitigates much of the human subjectivity associated with reading mammography results—and reduces the repetitive work screening physicians are routinely subjected to—we’re making breast cancer screening more effective, more measurable, and more accessible for everyone, everywhere. By democratising access to early screening around the world, we deliver measurable impact backed by clinical evidence. We are partnering globally, to deliver breast cancer screening where it is needed most.
TL;DR
Company: Vara — Berlin-based AI breast cancer screening platform
Product: AI-powered end-to-end population screening platform (booking, reading, reporting, follow-up)
Clinical evidence: Evaluated in large real-world studies including PRAIM
Employees: ≈54
Reported funding: Total reported ~$11.4M; Series A reported at $7M
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Breast cancer screening / diagnostic imaging workload and variability
Founded
2018
Industry
Hospitals and Health Care
Funding Track Record
$4,800,000
Seed round reported at $4.8M (note: some reporting relates to a different company named Vara; included here only where associated with vara.ai)
$7,000,000
Series A reported at $7M with participation from Merantix, Think.Health, Soleria Capital and Plug and Play